BidaskClub upgraded shares of Haemonetics Corporation (NYSE:HAE) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday.

A number of other research firms also recently commented on HAE. Zacks Investment Research downgraded shares of Haemonetics Corporation from a hold rating to a sell rating in a report on Tuesday, May 9th. Jefferies Group LLC reiterated a buy rating and issued a $42.00 target price on shares of Haemonetics Corporation in a report on Monday, May 8th. Barrington Research upgraded shares of Haemonetics Corporation from a market perform rating to an outperform rating and set a $48.00 target price on the stock in a report on Tuesday. TheStreet downgraded shares of Haemonetics Corporation from a b- rating to a c rating in a report on Monday, May 8th. Finally, JMP Securities upgraded shares of Haemonetics Corporation from a market perform rating to an outperform rating and set a $50.00 target price on the stock in a report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $40.63.

Shares of Haemonetics Corporation (NYSE:HAE) traded up 1.97% on Tuesday, reaching $42.50. 287,171 shares of the company’s stock traded hands. Haemonetics Corporation has a 52 week low of $32.76 and a 52 week high of $43.74. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of 551.95 and a beta of 0.90. The company has a 50 day moving average price of $40.24 and a 200 day moving average price of $40.17.

Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The company had revenue of $211 million for the quarter, compared to the consensus estimate of $211.29 million. During the same period in the previous year, the firm earned $0.25 EPS. Haemonetics Corporation’s revenue was up .5% on a year-over-year basis. On average, equities research analysts predict that Haemonetics Corporation will post $1.61 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Haemonetics Corporation (NYSE:HAE) Upgraded at BidaskClub” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/08/12/haemonetics-corporation-nysehae-upgraded-at-bidaskclub.html.

In related news, Director Ronald Merriman sold 17,471 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $40.33, for a total transaction of $704,605.43. Following the transaction, the director now directly owns 24,925 shares of the company’s stock, valued at $1,005,225.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in HAE. Norges Bank bought a new position in shares of Haemonetics Corporation during the fourth quarter worth approximately $20,512,000. Teachers Advisors LLC increased its position in shares of Haemonetics Corporation by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 85,025 shares of the medical instruments supplier’s stock worth $3,418,000 after buying an additional 2,081 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Haemonetics Corporation by 1.9% in the first quarter. Louisiana State Employees Retirement System now owns 21,200 shares of the medical instruments supplier’s stock worth $860,000 after buying an additional 400 shares during the last quarter. Legato Capital Management LLC increased its position in shares of Haemonetics Corporation by 3,957.0% in the first quarter. Legato Capital Management LLC now owns 54,202 shares of the medical instruments supplier’s stock worth $1,336,000 after buying an additional 52,866 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Haemonetics Corporation by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock worth $232,000 after buying an additional 130 shares during the last quarter.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Analyst Recommendations for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.